Abstract
The integrin receptor αvβ3 has been shown to play a critical role in several distinct processes, such as angiogenesis, osteoclast-mediated bone resorption and tumor metastasis. Its expression is upregulated in newly synthesized blood vessels produced in response to a variety of tumors and purified angiogenic factors. Studies show that αvβ3 is a critical target downstream from perhaps all angiogenic factors. Proof-of-principle that αvβ3 antagonists such as monoclonal antibodies and small molecules block angiogenesis and tumor growth has been obtained in several animal models. Many endogenous inhibitors of angiogenesis such as angiostatin, endostatin and tumstatin seem to work through the αvβ3 receptor further emphasizing the critical role of this receptor in angiogenesis. In addition, the αvβ3 receptor has been clearly implicated in several pathological processes such as rheumatoid arthritis, osteoporosis, and metastasis of prostate cancer to bone. Thus αvβ3 may prove to be an important target for pharmacological intervention in more than one clinical setting.
Keywords: integrin family, integrin, tumor-induced angiogenesis, alpha v beta 3
Current Drug Targets
Title: Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis
Volume: 4 Issue: 2
Author(s): C. Chandra Kumar
Affiliation:
Keywords: integrin family, integrin, tumor-induced angiogenesis, alpha v beta 3
Abstract: The integrin receptor αvβ3 has been shown to play a critical role in several distinct processes, such as angiogenesis, osteoclast-mediated bone resorption and tumor metastasis. Its expression is upregulated in newly synthesized blood vessels produced in response to a variety of tumors and purified angiogenic factors. Studies show that αvβ3 is a critical target downstream from perhaps all angiogenic factors. Proof-of-principle that αvβ3 antagonists such as monoclonal antibodies and small molecules block angiogenesis and tumor growth has been obtained in several animal models. Many endogenous inhibitors of angiogenesis such as angiostatin, endostatin and tumstatin seem to work through the αvβ3 receptor further emphasizing the critical role of this receptor in angiogenesis. In addition, the αvβ3 receptor has been clearly implicated in several pathological processes such as rheumatoid arthritis, osteoporosis, and metastasis of prostate cancer to bone. Thus αvβ3 may prove to be an important target for pharmacological intervention in more than one clinical setting.
Export Options
About this article
Cite this article as:
Kumar Chandra C., Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis, Current Drug Targets 2003; 4 (2) . https://dx.doi.org/10.2174/1389450033346830
DOI https://dx.doi.org/10.2174/1389450033346830 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Developments on Thiourea Based Anticancer Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry L-Sulforaphane Confers Protection Against Oxidative Stress in an In Vitro Model of Age-Related Macular Degeneration
Current Molecular Pharmacology Resveratrol and Its Analogues: Promising Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Management of Prostate Cancer with Systemic Therapy: A Prostate Cancer Unit Perspective
Current Cancer Drug Targets Synthesis and Antiproliferative Activity of 3-aza Steroids as 5α-reductase Inhibitors
Letters in Drug Design & Discovery Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry Anaesthesia in Cancer Surgery: Can it Affect Cancer Survival?
Current Clinical Pharmacology Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology New Insights in the Gene Electrotransfer Process: Evidence for the Involvement of the Plasmid DNA Topology
Current Gene Therapy Biomarkers of Asthma: Recent Patents from 2009-2011
Recent Patents on Biomarkers Current Progress of Reelin in Development, Inflammation and Tissue Remodeling: From Nervous to Visual Systems
Current Molecular Medicine VEGF and Colon Cancer Growth Beyond Angiogenesis: Does VEGF Directly Mediate Colon Cancer Growth Via a Non-angiogenic Mechanism?
Current Pharmaceutical Design Molecular Probing and Imaging of Histone Deacetylase Inhibitors in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Progress Towards Clinically Useful Aldosterone Synthase Inhibitors
Current Topics in Medicinal Chemistry Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Novel Drug Therapies for Fertility Preservation in Men Undergoing Chemotherapy: Clinical Relevance of Protector Agents
Current Medicinal Chemistry Role of Histone Acetylation in Cell Cycle Regulation
Current Topics in Medicinal Chemistry Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer Disorders
Current Topics in Medicinal Chemistry Cancer as the Main Aging Factor for Humans: The Fundamental Role of 5-Methoxy-Tryptamine in Reversal of Cancer-Induced Aging Processes in Metabolic and Immune Reactions by Non-melatonin Pineal Hormones
Current Aging Science Development of Peptides as Potential Drugs for Cancer Therapy
Current Pharmaceutical Design